WO2010082804A3 - Method for producing physiologically active protein or peptide using immunoglobulin fragment - Google Patents

Method for producing physiologically active protein or peptide using immunoglobulin fragment Download PDF

Info

Publication number
WO2010082804A3
WO2010082804A3 PCT/KR2010/000342 KR2010000342W WO2010082804A3 WO 2010082804 A3 WO2010082804 A3 WO 2010082804A3 KR 2010000342 W KR2010000342 W KR 2010000342W WO 2010082804 A3 WO2010082804 A3 WO 2010082804A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
physiologically active
active protein
immunoglobulin fragment
producing physiologically
Prior art date
Application number
PCT/KR2010/000342
Other languages
French (fr)
Other versions
WO2010082804A2 (en
Inventor
Jin-Sun Kim
Sung Youb Jung
Jong-Soo Lee
Byung Sun Lee
Se Chang Kwon
Gwan Sun Lee
Original Assignee
Hanmi Holdings Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co., Ltd filed Critical Hanmi Holdings Co., Ltd
Publication of WO2010082804A2 publication Critical patent/WO2010082804A2/en
Publication of WO2010082804A3 publication Critical patent/WO2010082804A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present invention provides a method for mass-producing a physiologically active protein or peptide using a fusion protein composed of the physiologically active protein or peptide and an immunoglobulin fragment. The present invention also provides such a fusion protein, a DNA encoding the fusion protein, an expression vector comprising the DNA, and a microorganism transformed with the expression vector.
PCT/KR2010/000342 2009-01-19 2010-01-19 Method for producing physiologically active protein or peptide using immunoglobulin fragment WO2010082804A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0004234 2009-01-19
KR20090004234 2009-01-19

Publications (2)

Publication Number Publication Date
WO2010082804A2 WO2010082804A2 (en) 2010-07-22
WO2010082804A3 true WO2010082804A3 (en) 2010-11-25

Family

ID=42340231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/000342 WO2010082804A2 (en) 2009-01-19 2010-01-19 Method for producing physiologically active protein or peptide using immunoglobulin fragment

Country Status (4)

Country Link
KR (1) KR20100084996A (en)
AR (1) AR075029A1 (en)
TW (1) TW201031752A (en)
WO (1) WO2010082804A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2348114B1 (en) 2004-04-21 2018-07-25 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
EP3226891A1 (en) 2014-12-05 2017-10-11 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (en) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド Identifying effective dosing regimens for tissue-nonspecific alkaline phosphatase (TNSALP) enzyme replacement therapy for hypophosphataseemia
JP2018533571A (en) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド Methods for treating cranial suture early healing disease in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2020060202A1 (en) * 2018-09-18 2020-03-26 한국생산기술연구원 Expression cassette for preparing thymulin or argireline, and use thereof
KR102124035B1 (en) * 2018-09-18 2020-06-19 한국생산기술연구원 A expression cassette for preparation of thymulin and use thereof
CN111208243B (en) * 2018-11-21 2022-05-17 中国科学院大连化学物理研究所 Anion exchange chromatographic column-based SUMO peptide fragment enrichment method

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196321A (en) * 1986-10-02 1993-03-23 Massachusetts Institute Of Technology Methods for in vitro cleavage of ubiquitin fusion proteins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US20050124045A1 (en) * 2001-08-17 2005-06-09 Sun Lee-Hwei K. Fc fusion proteins of human erythropoietin with increased biological activities
US20060269553A1 (en) * 2003-11-13 2006-11-30 Hanmi Pharm. Ind. Co., Ltd. Protein complex using an immunoglobulin fragment and method for the preparation thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196321A (en) * 1986-10-02 1993-03-23 Massachusetts Institute Of Technology Methods for in vitro cleavage of ubiquitin fusion proteins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US20050124045A1 (en) * 2001-08-17 2005-06-09 Sun Lee-Hwei K. Fc fusion proteins of human erythropoietin with increased biological activities
US20060269553A1 (en) * 2003-11-13 2006-11-30 Hanmi Pharm. Ind. Co., Ltd. Protein complex using an immunoglobulin fragment and method for the preparation thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LO K. M. ET AL, PROTEIN ENGINEERING, vol. 11, no. 12, June 1998 (1998-06-01), pages 495 - 500 *

Also Published As

Publication number Publication date
KR20100084996A (en) 2010-07-28
AR075029A1 (en) 2011-03-02
WO2010082804A2 (en) 2010-07-22
TW201031752A (en) 2010-09-01

Similar Documents

Publication Publication Date Title
WO2010082804A3 (en) Method for producing physiologically active protein or peptide using immunoglobulin fragment
NZ596658A (en) Dig-10 insecticidal cry toxins
WO2010042654A3 (en) Recombinant nell protein production
WO2013184939A3 (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
WO2011064758A3 (en) Fusion proteins of immunoglobulin fc and interferon- alpha
WO2009142460A3 (en) Antibody-peptide fused synergibody
WO2008140812A3 (en) Compositions and methods comprising klk3, psca, or folh1 antigen
WO2011069164A3 (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
IL195191A (en) Fusion proteins, nucleic acids encoding same and processes for producing same
WO2006127757A3 (en) Interferon-igg fusion
WO2013059885A3 (en) Polypeptide constructs and uses thereof
WO2009009523A3 (en) Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2012142515A3 (en) Fc fusion proteins comprising novel linkers or arrangements
WO2009136286A3 (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
ATE527345T1 (en) CHIMERIC FUSION PROTEIN WITH SUPERIOR CHAPERONE AND FOLDING ACTIVITIES
WO2012048332A3 (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
WO2007001264A3 (en) Method of making recombinant human antibodies for use in biosensor technology
WO2007112757A3 (en) A process for concentration of a polypeptide
NZ596735A (en) Recombinant production of peptides
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
WO2008100470A3 (en) Rage - immunoglobulin fusion proteins
WO2008085900A3 (en) Methods for generating novel stabilized proteins
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
EP3976642A4 (en) Apoe antibodies, fusion proteins and uses thereof
WO2007115724A3 (en) Method of increasing the in vivo recovery of therapeutic polypeptides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10731419

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10731419

Country of ref document: EP

Kind code of ref document: A2